Trailing Twelve Months Revenue Growth: BeyondSpring Inc (BYSI)

Public company logo of beyondspringpharma.com (BYSI)

BeyondSpring Inc. automates the search for oncology targets using AI and robotics. The current 12-month trailing revenue dynamics on this GURU.Markets chart illustrate expansion rates, where 0.00 captures the current state of the parameter. High FDA barriers and patent protection limit competition, although a liquidity deficit resulting from global operational costs necessitates a secondary offering.

BeyondSpring Inc. (BYSI): Revenue Growth YoY (Last 12 Months) from 02/11/2024 to 11/15/2026

BeyondSpring Inc. - analytical breakdowns and key metrics (BYSI)

- stock price and consensus target price:
Price Chart BeyondSpring Inc|BYSI - Price Target Chart
- company stock exchange capitalization indicators:
Market Value BeyondSpring Inc.|BYSI - Enterprise Value
- book capitalization data:
Book Value of One Share BeyondSpring|BYSI - Company Net Assets|Market-to-Book Ratio beyondspringpharma.com|BYSI - Cumulative Company Assets
- business debt structure and liquidity details:
All Debt to Shareholders' Equity Ratio BeyondSpring Inc.|BYSI - Long-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio BeyondSpring|BYSI - Company Aggregate Debts|Debt to Net Assets Ratio BeyondSpring Inc.|BYSI - Company Long-Term Debts|Short-Term Debt BeyondSpring|Intermediate Coverage Ratio beyondspringpharma.com
- net income and valuation ratios data:
BYSI - Net Profit|Projected Future Earnings BeyondSpring Inc.|BYSI - Price to Earnings Ratio|Price to Expected Earnings Ratio BeyondSpring|BYSI - Price/Earnings to Growth Multiple|Company Value to EBITDA BeyondSpring Inc.|BYSI - Operating profit EBITDA|Earnings per share for the last twelve months BeyondSpring|BYSI - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months beyondspringpharma.com|BYSI - Net earnings per share growth this year|Expected net earnings per share growth next year BeyondSpring Inc.
- sales and revenue indicators:
BYSI - Company Revenue|Company Expected Sales Volume BeyondSpring Inc|BYSI - Price-to-Revenue Ratio|Market Cap to Projected Revenue BeyondSpring Inc.|BYSI - Sales Growth YoY (TTM)
Summary company analytics:BeyondSpring Pharma
Brand item of BeyondSpring Inc

BeyondSpring Inc. specializes in the development of plinabulin for the treatment of oncology and neutropenia. The rolling 12-month sales growth relative to the same period last year visualizes revenue expansion rates in real time. This metric measures the percentage deviation of current annual income from the corresponding period of the previous year. For BeyondSpring Inc., this is the primary marker of commercialization efficiency for its drugs in the US and China. A slowdown in growth signals business stagnation and risks of frozen investments.

Who BeyondSpring Inc. competes with

Incyte Pharma - Sales Growth YoY (Last Twelve Months)|HUTCHMED Corp - Sales Growth YoY (TTM)|Trailing Twelve Months Revenue Growth Nuvation Bio Inc.|DAWN: Sales Growth YoY (TTM)|Revenue Growth Rate YoY (Last Twelve Months) Monopar Pharma MNPR|Revenue Growth YoY (Last 12 Months) INBX|Trailing Twelve Months Revenue Growth I-Mab Biopharma IMAB|Revenue Growth YoY (Last 12 Months) FENC (Fennec Pharmaceuticals)|HRTX (Heron Therapeutics Inc) - Revenue Dynamics YoY (Last Twelve Months)|Nuvectis Pharma, Inc. - Revenue Growth YoY (Last 12 Months)|Revenue Change YoY (Last 12 Months) CHRS (Coherus BioSciences)|Corbus Pharma - Sales Growth YoY (TTM)|Revenue Dynamics YoY (Last Twelve Months) CRDF (cardiffoncology.com)|BCAB: Sales Growth YoY (TTM)|Trailing Twelve Months Revenue Growth lixte.com (LIXT)|Sales Growth YoY (Last Twelve Months) citiuspharma.com|CLRB: Revenue Dynamics YoY (Last Twelve Months)|Sales Growth YoY (TTM) BLRX|Sales Growth YoY (TTM) Can-Fite (CANF)|Sales Growth YoY (Last Twelve Months) Aprea Therapeutics Inc. APRE|KZIA (kaziatherapeutics.com) - Trailing Twelve Months Sales Growth|SLXN: Revenue Growth YoY (Last 12 Months)|Trailing Twelve Months Revenue Growth NuCana|CMRX: Sales Growth YoY (TTM)|Revenue Growth YoY (Last 12 Months) Cyclacel Pharmaceuticals|GTHX (g1therapeutics.com) - Sales Growth YoY (TTM)|KRON: Revenue Dynamics YoY (Last Twelve Months)|Sales Growth YoY (Last Twelve Months) Kintara (KTRA)|Revenue Growth YoY (Last 12 Months) Oncternal ONCT|Portage Biotech - Revenue Growth YoY (Last 12 Months)